Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official claimed the shots led to 10 children’s deaths and said the agency would tighten ...

Shares of vaccine makers fell Monday after the Food and Drug Administration said in an internal memo that it would introduce stricter vaccine approval rules.

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...